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The term “equine asthma” has been proposed as a unifying descriptor of inflammatory airway
disease (IAD), recurrent airway obstruction (RAO), and summer pasture-associated obstructive
airway disease. Whilst the term will increase comprehensibility for both the lay and scientific
communities, its biologic relevance must be compared and contrasted to asthma in human medi-
cine, recognizing the limited availability of peer-reviewed equine-derived data, which are largely
restricted to clinical signs, measures of airway obstruction and inflammation and response to
therapy. Such limitations constrain meaningful comparisons with human asthma phenotypes.
Suggested minimum inclusion criteria supporting the term asthma, as well as similarities and dif-
ferences between IAD, RAO, and multiple human asthma phenotypes are discussed. Further-
more, differences between phenotype and severity are described, and typical features for
equine asthma subcategories are proposed. Based on shared features, we conclude that mild/
moderate (IAD) and severe (RAO) equine asthma are biologically appropriate models for both
allergic and non-allergic human asthma, with RAO (severe equine asthma) also being an appro-
priate model for late-onset asthma. With the development of new biologic treatments in
humans and the application of more targeted therapeutic approaches in the horse, it would
appear appropriate to further investigate the allergic (Th-2) and non-allergic (non-Th-2) pheno-
types of equine asthma. Further research is required to more fully determine the potential clini-
cal utility of phenotype classification.
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1 | INTRODUCTION
Numerous terms have been used to describe chronic inflammatory
lower airway disease in horses, including heaves, recurrent airway
obstruction (RAO), equine chronic obstructive pulmonary disease,
inflammatory airway disease (IAD), tracheal IAD, bronchial IAD, small
airway disease, chronic bronchitis, summer pasture-associated chronic
obstructive pulmonary disease, summer pasture-associated obstruc-
tive pulmonary disease, summer pasture-associated obstructive air-
way disease, summer heaves, and summer RAO. Progressive
awareness of various clinical and pathological features of equine
inflammatory lower airway disease precipitated the evolution of the
above nomenclature; however, this has become unsustainable, result-
ing in confusion within both the veterinary and lay communities. It
has recently been proposed that chronic non-infectious inflammatory
lower airway disease in horses be reassigned the designation “equine
asthma.”1–3 As highlighted during the 6th World Equine Airway
Abbreviations: AP-1, activator protein-1; ASM, airway smooth muscle; BAL,
bronchoalveolar lavage; BALF, bronchoalveolar lavage fluid; CXCL2, chemokine
(C-X-C motif ) ligand 2; ECM, extracellular matrix; IAD, inflammatory airway dis-
ease; IFN, interferon; IL, interleukin; IL4Rα, IL-4 receptor α-chain; LT, leukotri-
ene; NF-κB, nuclear factor-κb; RAO, recurrent airway obstruction; TNF, tumor
necrosis factor
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Symposium (2017), the biological appropriateness of applying the
term “equine asthma” must be considered in light of its current use in
human medicine before its widespread adoption in the veterinary lit-
erature.4 Increasing comprehensibility amongst the horse-owning
public and the veterinary profession would constitute a clear benefit
of the newly proposed terminology; however, the validity and limita-
tions of the proposed change in nomenclature must first be consid-
ered and described. Before the proposed use of the term “equine
asthma,” RAO/Heaves, and IAD have been widely used and accepted
because of their accurate descriptions of the disease processes to
which they refer. While a distinction between these 2 phenotypes
was initially proposed for research purposes to facilitate comparison
between study results,5,6 it was not the intent of the workshop partic-
ipants to suggest that they were 2 separate conditions. However, dif-
ferent names lead clinicians to subsequently consider them to be
distinct and both have individually been the subject of expert panels'
workshops5,7,8 and publications.1,6,9 In contrast to, and distinct from
IAD, horses with RAO exhibit increased respiratory effort at rest.6
This distinguishing feature is attributable to the magnitude of bronch-
oconstriction, increased mucus production and bronchiolar inflamma-
tion associated with this disorder.9,10 While IAD and RAO are
considered as separate diseases, it is presently unclear whether this
distinction reflects a dissimilar pathogenesis, or simply a difference in
the clinical severity. There are many factors which potentially differ
(ie, clinical signs, pathogenesis, recurrence) among the spectrum of
diseases which fall within the proposed new “equine asthma” classifi-
cation, including severity of clinical signs, pathogenetic pathways, and
rates of recurrence. Therefore, further differentiation of the term into
mild, moderate, and severe equine asthma has been advocated.2
Although application of these qualifying terms is currently limited to
clinical severity, with mild/moderate and severe equine asthma being
analogous to IAD and RAO, respectively,2 it is hoped that future sub-
classification efforts might consider additional criteria such as patho-
genetic pathways and immunological characteristics. The aims of this
review are to: (1) propose minimum inclusion criteria supporting utili-
zation of the term “equine asthma,” (2) compare and contrast features
of equine asthma with the most common human asthma phenotypes,
(3) propose typical features for subcategories of equine asthma, and
(4) provide recommendations for future research directions.
2 | INCLUSION CRITERIA
The biological appropriateness of the term “equine asthma” must be
considered relative to its current use in human medicine. It is impor-
tant to consider both a minimum set of criteria shared by all human
and equine asthma phenotypes, as well as additional criteria shared
between specific human and equine asthma phenotypes.4
3 | MINIMUM INCLUSION CRITERIA FOR
APPLICATION OF THE TERM “ASTHMA”
Asthma in humans is a heterogeneous disease characterized by non-
septic chronic airway inflammation.11 Patients have a history of signs
of respiratory disease (coughing, wheezing, shortness of breath and
tightness of the chest) which vary in intensity and over time, com-
bined with airway hyperresponsiveness and expiratory airflow limita-
tion of fluctuating severity.11 Bronchoconstriction, airway wall
thickening, increased mucus secretion, and airway remodeling are
accompanying this phenotype.11 With the exception of shortness of
breath and chest tightness, which, as subjective descriptors of a per-
ceived sensation, are not feasibly applicable to the horse, this pheno-
type is largely shared by both IAD and RAO. Horses with RAO exhibit
the same pathophysiologic features as human asthma; namely bronch-
oconstriction, airway wall thickening, increased mucus production and
airway remodeling.12,13 This pathophysiology is associated with the
increased respiratory effort observed at rest in horses with RAO.13
Horses with IAD have inflammation of the trachea and bronchi, with
an excessive accumulation of mucus in the airways,14,15 resulting in a
mild increased resistance to airflow.16–18 Mild equine asthma
decreases racing performance in Thoroughbred racehorses.19 The
pathology exhibited by horses with IAD typically manifests in clinical
signs that are subtle at rest, with horses exhibiting chronic (>3 weeks)
occasional coughing and normal respiratory effort1; and coughing,
increased nasal discharge, poor performance, or a combination of
these during exercise.1 Impaired pulmonary gas exchange limits per-
formance, and intensely exercising horses with IAD have worsening of
exercise-induced hypoxemia.20–22 However, the bronchoconstriction
in horses with IAD is sufficiently mild to evade clinical detection via
the appreciation of increased respiratory effort at rest without
bronchoprovocation. Whilst airway remodeling has not yet been stud-
ied in horses with IAD, peribronchiolar infiltration of inflammatory
cells (82/95 horses) and bronchiolar smooth muscle hyperplasia
(93/95 horses) are common in racehorses.23 Although eosinophils or
mast cells (or both) are present in the bronchiolar wall of some race-
horses, it was not possible for the authors to determine if these find-
ings correspond to a clinical diagnosis of IAD.23 Notably absent from
this list of minimum inclusion criteria is the predominant airway
inflammatory cell; this notable omission is further discussed in
Section 7.
4 | DIAGNOSIS
A diagnosis of asthma in human patients with signs of respiratory dis-
ease is initially based on a detailed clinical history, physical examina-
tion (which can be normal at the time of presentation), radiography,
and screening questionnaires.24,25 Despite the value of context-
specific questionnaires in positively screening for high-risk chronic air-
way disease patients, international guidelines emphasize the diagnos-
tic importance of spirometry.11 This is especially pertinent considering
the shared features common to both asthma and chronic obstructive
pulmonary disease. Similarly, a presumptive diagnosis of IAD or RAO
is generally based on the horses' history and clinical presentation, the
latter of which has been incorporated into both the independently val-
idated risk-screening questionnaire (RSQ) and horse owner assessed
respiratory signs index (HOARSI).26,27 Whilst these clinical-sign–based
screening tools have both excellent sensitivity and negative predictive
values for detecting severe lower airway inflammation (RAO), they fail
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to differentiate between healthy horses and those with mild airway
inflammation (IAD).28–30 Furthermore, in light of the poor diagnostic
sensitivity of coughing, mucoid nasal discharge and poor performance,
reliance is placed on additional tests, such as tracheal endoscopy,
bronchoalveolar lavage fluid (BALF) cytology and lung function
evaluation,1 in an attempt to maximize diagnostic accuracy of both
RAO and IAD.
5 | ADDITIONAL INCLUSION CRITERIA
BETWEEN SPECIFIC HUMAN ASTHMA AND
IAD/RAO PHENOTYPES
Any efforts to advocate equine asthma as an appropriate disease
model for the study of human asthma must take into consideration
the fact that multiple human asthma phenotypes exist, not all of which
will share attributes with RAO and IAD. Similar considerations also
relate to the translational application of human asthma-derived scien-
tific findings to the horse, and vice versa. Therefore, the appropriate-
ness of any such cross-species comparisons necessitates the
application of additional criteria which specifically distinguish certain
human asthma and IAD/RAO phenotypes based on disease-specific
key features. It has been proposed that RAO is an ideal equine model
for the study of non-allergic, late-onset, and severe asthma pheno-
types31; however, the biologic appropriateness of IAD for the study of
specific human asthma phenotypes has not yet been investigated and
is a focus of this review.
6 | PHENOTYPE VERSUS SEVERITY
An “asthma phenotype” is a recognizable cluster of demographic, clini-
cal, pathophysiological, or any combination of these
characteristics32–34; however, these do not always have a strong cor-
relation with specific pathologic processes, or even treatment
responses.11 In humans, various asthma management guidelines have
described methods to categorize asthma severity; however, there are
substantial theoretical and practical differences between recommen-
dations.35 Asthma severity is differentiated into mild, moderate and
severe categories11 and is predominantly based on the level of treat-
ment required to control symptoms and exacerbation; it is not a static
feature of the disease and changes over time. In some instances, it is
also used to describe the intensity of symptoms or the magnitude of
airflow limitation. However, these approaches do not focus on quanti-
fying markers of airway inflammation, which would assess the severity
of the disease process itself. For practical reasons, asthma is only clas-
sified after institution of effective treatment and therefore assess-
ment is always subject to treatment effect. To date, there are no
treatment-naive predictors of disease severity.
It has been proposed that mild/moderate equine asthma replace
IAD, and severe equine asthma replace RAO.1,2 Certain criteria have
recently been proposed for the subcategorization of equine asthma
based on severity. Specific cutoff values or recommendations were
proposed for the following methods: clinical presentation, airway
endoscopy, airway cytology, and pulmonary function tests.36
However, applicability of these criteria to RAO and IAD subcategori-
zation remains arbitrary. A meta-analysis of published studies based
on client-owned horses with IAD and RAO would likely offer valuable
information on the relative contributions of each of the above criteria
to the overall equine asthma subcategorization exercise. Moreover, a
poor correlation exists between specific diagnostic results (ie, severe
inflammatory bronchoalveolar lavage [BAL] profile) and clinical signs
(ie, increased respiratory effort at rest). Although the inclusion of
severity of clinical signs as a key criterion in the subcategorization of
equine asthma is easy to comprehend (particularly among the horse-
owning public), it should not be applied exclusively, particularly in light
of the inconsistent correlation between severity of airway inflamma-
tion and clinical signs in both human11 and equine asthma.37–39
Despite the challenges facing any effort to further subcategorize
equine asthma, such an exercise can clearly be justified by its potential
to reveal more specific therapeutic and prophylactic targets.
7 | PHENOTYPES
There is a need to identify and apply criteria to further subcategorize
equine asthma, and it has been suggested that a new classification
based on immunological signature data could have greater relevance,4
particularly in the context of novel, targeted biologic therapeutic
approaches.40 In humans, it is recognized that asthma is a heteroge-
neous disease, with the underlying pathogenesis differing among phe-
notypes.11 There is evidence that RAO has a genetic background with
possible locus heterogeneity41 (discussed in Section 8). In comparison,
while genetic susceptibility is suspected in IAD, it has not been inves-
tigated. In light of the biologic characteristics common to both equine
and human asthma and the marked disease heterogeneity in both,
endeavoring to apply currently defined human asthma phenotypes to
the horse seems to represent a logical starting point in the process of
equine asthma subcategorization. There are multiple human asthma
phenotypes, the most common of which are allergic asthma, non-
allergic asthma, late-onset asthma, asthma with fixed airflow limita-
tion, and asthma in obese patients.11 While RAO and IAD do not nec-
essarily share attributes with all phenotypes, similarities and
differences between these equine diseases and human asthma are dis-
cussed below, and summarized in Table 1. Furthermore, Table 1 also
identifies the equine diseases which, at this time, the authors propose
to be biologically appropriate models for each human asthma pheno-
type. The authors acknowledge the requirement for further research
to better support these preliminary proposals. Our review aims to
focus on the biologic relevance of the proposed nomenclature; how-
ever, for an extensive discussion of the advantages and disadvantages
of the equine asthma model, the reader is referred to the excellent
review article.31
8 | ALLERGIC ASTHMA
One of the most common human asthma phenotypes is “allergic
asthma,” a term which reflects the triggering role of allergens in this
particular subgroup. Allergic asthma is generally associated with a
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TABLE 1 Features of asthma phenotypes in humans and IAD/RAO in horses, appropriateness of equine asthma model, and areas identified for
future research
Asthma
phenotype Features in humans
Features supporting phenotype
model in horses
Equine
model
appropriate?
Areas identified for future equine
research
Allergic asthma • Allergenic trigger
associated with
respiratory symptoms/
expiratory airflow
limitation
• Often commences in
childhood
• Past/family history of
allergic disease (eczema/
allergic rhinitis/food or
drug allergy)
• Sputum often reveals
eosinophilic airway
inflammation
• Usually respond well to
ICS treatment
• Th-2 CD4+ lymphocyte
response—IL-5–mediated
eosinophil recruitment
• IL4Rα gene associated
with the development of
asthma, skin allergies and
parasite defense
IAD
• Antigenic triggers central to
development of lower airway
inflammation
• Stabling exposes horses to high
levels of airborne particulates (eg,
dust, endotoxin, fungi, molds,
ultrafine particles, noxious gases),
and is a risk factor for IAD
• Antigenic triggers (eg, dust, mold
spores) associated with increased
neutrophil/mast cell% in BALF
• Antigenic triggers associated with
clinical signs (eg, coughing, poor
performance)
• Often occurs in young horses
• Eosinophilic phenotype associated
with dust exposure in young horses
• Usually respond well to ICS
treatment
• Th-2 response—Increase in IL-4 and
IL-5 in BALF linked with mastocytic
phenotype
Yes • Eosinophil involvement in
pathogenesis of IAD
• Effect of BALF phenotype on
performance
• Role of IgE in IAD and RAO
• Longitudinal and cross-sectional
studies investigating an “atopic
march” in horses
• Comprehensive study investigating
the effect of various allergenic
triggers on both lower airway
pathology and clinical signs (ie,
investigate causality rather than
association)
RAO
• Allergenic trigger (molds  LPS)
associated with clinical signs and
pathology (increased neutrophil % in
BALF, increased respiratory effort
at rest)
• Associated with multiple
hypersensitivities in some families of
horses (insect bite hypersensitivity,
urticaria, increased parasite
resistance)
• Good response to ICS
• Association between IL4Rα and RAO
• IL4Rα upregulates IL-4 expression
during disease exacerbation, which
promotes isotype switching from
IgM to IgE
• Increased IgE in BALF in horses
with RAO
Yes
Non-allergic
asthma
• Not associated with
allergy
• Sputum can be
neutrophilic eosinophilic
or paucigranulocytic
• Often respond less well
to ICS
• Chronically activated
mast cells in bronchial
mucosa (can be
associated with
non-allergenic stimulus)
• Th-1 response—
cell-mediated immunity
and
phagocyte-dependent
inflammation
IAD
• BALF can reveal neutrophilia and/or
eosinophilia and/or mast cells
accumulation
• Th-1 response—mRNA encoding
TNF-α, IL-1β, and IFN-γ in BALF
• Th-17 response—Increase in IL-17
and IL-23 linked with increased
neutrophil % in BALF
• Often respond less well to ICS
Yes • Role of neutrophil/mast cell
activation in the development of
lower airway inflammation
RAO
• BALF can be neutrophilic or
paucigranulocytic (in severe cases
where BALF return is low)
• Chronic innate immune activation -
chronic activation of peripheral
neutrophils
• Often respond less well to ICS
Yes
Late-onset
asthma
• Initial presentation as
adult (particularly
women)
• Less likely to be atopic
• Decreased baseline
pulmonary function
• Often refractory to
ICS/require higher doses
for control
IAD
• Insufficient evidence
No • Disease progression from IAD to
RAO over time
• Correlation between inflamm-aging
and development of chronic
inflammatory airway disease
RAO
• Decreased baseline pulmonary
function during disease exacerbation
• Mature/older animals
• Can require higher doses for control
Yes
(Continues)
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past/family history of allergic disease (eg, eczema, food allergy) and
pretreatment induced sputum from affected patients often reveals
eosinophilic airway inflammation33; the response to inhaled cortico-
steroid treatment is generally favorable. Currently, IAD in the horse
can be further subcategorized based on the predominant inflamma-
tory cell in BALF; namely, neutrophilic, eosinophilic, mastocytic, or
mixed granulocytic. Whilst the pathogenesis of IAD is incompletely
defined, it is widely understood to be a multifactorial disease with the
relative contribution of etiological influences varying with environ-
ment, husbandry, location, season, and preventive medicine strate-
gies.42,43 Antigenic triggers are central to the development of lower
airway inflammation. Horses kept in conventional stables with poor
ventilation are exposed to high levels of airborne particulates44 includ-
ing dust, endotoxin, fungi, molds, ultrafine particles and noxious gases,
and there is strong evidence that stabling of horses is a risk factor for
IAD.45–48 However, the level of respirable particulates in the overall
stall air does not necessarily reflect the level of challenge a horse
experiences, as the majority of dust exposure occurs in the breathing
zone during feeding.48 Exposure to hay and its accompanying mold
spores, such as Aspergillus fumigatus, Saccharopolyspora rectivirgula,
and Thermoactinomyces vulgaris, are a risk factor in the development
of lower airway inflammation.28,49,50 Furthermore, compared to feed-
ing hay from the ground feeding hay in a net has a 4-fold increase in
breathing zone respirable particle concentration.48 There is little infor-
mation regarding an association between antigenic triggers (ie, dust,
mold spores) and specific IAD phenotypes. A prospective, cross-over
study did reveal an association between stabling of young horses and
an IAD phenotype characterized by increased airway neutrophils.45
This phenotype has been associated with coughing and poor perfor-
mance (discussed above in minimum inclusion criteria for application
of the term “asthma”), both of which form the basis for the diagnosis
of IAD. In contrast with the human allergic asthma phenotype, eosino-
phils are less commonly detected in equine BALF, with the exception
of a subgroup of IAD mainly found in young horses yet with an overall
prevalence lower than other IAD cytological subtypes.28,51–53 In
young horses, the recruitment of airway eosinophils appears to be
associated with dust exposure43,44 and increased BALF eosinophil
ratios have been associated with pulmonary hyperresponsiveness.54
Further studies are clearly warranted to more fully clarify the role of
eosinophils in IAD pathogenesis and their effect on respiratory func-
tion.1 Nevertheless, regardless of the BALF cytologic profile, it
appears that antigenic triggers are associated with both the clinical
signs and pathology of lower airway inflammation observed in horses
with IAD. Similarly, yet more widely reported in the literature, anti-
genic triggers are strongly associated with both clinical exacerbations
and pathologic changes (eg, airway remodeling) in horses with RAO.31
Of note, however, eosinophils are absent from the airway wall of
RAO-affected horses.55
In humans, an “atopic march” has been described, whereby the
first clinical manifestation of allergic disease, atopic dermatitis, is fol-
lowed by the subsequent development of food allergy, rhinitis, and
asthma.56 Evidence suggests that 75% of young children that experi-
ence severe atopic dermatitis will develop allergic rhinitis, and 50%
will develop asthma.57 In horses, while data supporting the existence
of an “atopic march” are lacking, there is genetic, epidemiological and
clinical evidence of multiple co-existing manifestations of allergic dis-
ease within a single individual. There is a genetic association between
RAO and microsatellite markers syntenic with the IL-4 receptor
α-chain (IL4Rα) gene on equine chromosome 13.41 Importantly, the
IL4Rα gene is associated with the development of asthma, skin aller-
gies, and parasite defense in humans.58–60 RAO is associated with
multiple hypersensitivities, including insect bite hypersensitivity61 and
urticaria,62 as well as increased parasite resistance63; specifically,
members of a half-sibling family with a high-incidence of RAO shed
fewer strongylid eggs compared to genetically unrelated RAO-
unaffected pasture mates. Furthermore, RAO-affected offspring
within the high-prevalence family had lower strongylid egg counts
than RAO-unaffected descendants. In this instance, the RAO-
TABLE 1 (Continued)
Asthma
phenotype Features in humans
Features supporting phenotype
model in horses
Equine
model
appropriate?
Areas identified for future equine
research
Asthma with
fixed airflow
limitation
• Chronic asthma patients
with fixed airflow
limitation; thought to be
because of airway wall
remodeling
• Increased airway smooth
muscle mass and
extracellular matrix at all
levels of bronchial tree
• Postbronchodilator
FEV1 < 70% (predicted)
IAD
• Insufficient evidence
No • Airway remodeling in IAD
• Reversibility of airway remodeling
in human asthmatics/horses with
IAD/horses with RAO; there is
limited data studying airway
remodeling of the peripheral
airways of human asthmatics and
reversibility in response to therapy,
and limited data available in horses
with RAO
RAO
• Tissue remodeling is reversible—
long-term antigen avoidance
strategies and corticosteroid therapy
decrease airway smooth muscle mass
and subepithelial collagen area
Insufficient
evidence
Asthma in
obese
patients
• Dyspnea on exertion
• Requires objective
measurement of variable
airflow limitation—
Obesity-associated
respiratory symptoms
can mimic asthma
• Little eosinophilic airway
inflammation
• Correlation between body condition
score and body fat (%) and increased
expression of IL-1 and TNF-α in
plasma
Insufficient
evidence
• Expression of inflammatory
cytokines in BALF or increased
pulmonary resistance in obese/
equine metabolic syndrome horses
Abbreviations: BALF, bronchoalveolar lavage fluid; FEV1, forced expiratory volume in 1 s; IAD, inflammatory airway disease; ICS, inhaled corticosteroid;
RAO, recurrent airway obstruction, TNF, tumor necrosis factor.
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phenotype was associated with the expression of microsatellite
markers near the IL4Rα gene, resulting in an upregulation of IL-4 dur-
ing RAO disease exacerbation.64 However, the association between
IL4Rα and RAO is neither absolute nor universal. The fact that it is not
observed in every high-prevalence RAO family supports the existence
of genetic heterogeneity within the currently defined RAO phenotype.
Although IL-4 promotes isotype switching from IgM to IgE,65 there is
inconclusive evidence within the veterinary literature regarding the
role of IgE in RAO; one study reported an increase in mold-specific
serum IgE in RAO horses compared with control horses,66 whilst sev-
eral studies failed to generate similar findings.67,68 There is an increase
in BALF IgE concentrations in horses with RAO.67 Whilst there are
presently no reports on the role of IgE in IAD, a Th-2 cytokine signa-
ture has been detected in BAL cells derived from mastocytic forms of
IAD, characterized by increased expression of IL-4 and IL-5
mRNA.69,70 Whilst further data, derived from longitudinal studies, are
required to support the existence of an “atopic march” in the horse,
an “allergic equine asthma” phenotype currently appears biologically
appropriate.
9 | NON-ALLERGIC ASTHMA
A common asthma phenotype in human adults is “non-allergic
asthma,” where there is no apparent association with allergy. Analysis
of pretreatment patient-derived sputum reveals neutrophilic, eosino-
philic, or paucigranulocytic inflammation. Paucigranulocytic asthma is
associated with normal or near-normal levels of eosinophils and neu-
trophils. Human asthma, particularly the allergic phenotype, displays
an IL-5–mediated eosinophil recruitment predominantly driven by a
Th-2 CD4+ lymphocyte response. However, the role of a Th-1
immune response and its ability to evoke cell-mediated immunity and
phagocyte-dependent inflammation is exhibited both in chronic
severe asthma and acute asthma exacerbations, the latter being asso-
ciated with airway neutrophil recruitment as early as 4 hours after
allergen exposure. Furthermore, in chronic asthma in humans, there
are persistently activated mast cells in the bronchial mucosa, evident
as elevated cytokine expression and synthesis.71–73 Although mast
cell activation is often assumed to be allergen induced, there are mul-
tiple non-allergenic stimuli which can cause this activation, including
proteases,74 cytokines,75 and Toll-like receptor ligands.75 These and
other mechanistic pathways are described in detail in a review arti-
cle.76 In addition to the varied mechanisms (both allergenic and non-
allergenic) which underpin mast cell degranulation, differences also
exist with respect to the kinetics of degranulation. In contrast to the
rapid mast cell degranulation observed after allergen challenge, the
ultrastructural appearance of some asthmatic airway mast cells
appears consistent with a slower degranulation process.73 Whilst mast
cells are well known for their role in allergic and anaphylactic reactions
(where rapid degranulation is observed as part of a Th-2-biased
response), increasing evidence supports an alternative role of mast
cells in inflammation, whereby they exhibit “differential” or “selective”
secretion of mediators without degranulation.77 Similarly, there is evi-
dence that both the Th-1 and Th-2 immune responses are involved in
the pathogenesis of IAD and RAO. However, when interpreting the
gene expression data derived from horses with IAD, it is important to
consider whether the diagnosis was based on a generalized increase
in airway inflammatory cells or an increase in a specific inflammatory
cell (neutrophilic, mastocytic, eosinophilic). Evidence of a Th-1
response in the lower respiratory tract, characterized by upregulation
of IFN-γ mRNA in BALF-derived cells, has repeatedly been reported
in association with a generalized increase in BAL inflammatory cells,
both in the presence and absence of clinical signs.53,70,78 Additionally,
a Th-17 response has been implicated in neutrophilic IAD, with an
association between the BALF neutrophil ratio and increased IL-17
and IL-23 mRNA expression.53,69 It is important to consider that these
responses might reflect sequential phases of the chronic inflammatory
process in the respiratory tract; consequently, it might not be appro-
priate to consider them as mutually exclusive.79 Such considerations
remain speculative, particularly in naturally occurring cases, and addi-
tional studies are required for clarification.
Chronic innate immune activation is a feature of both neutrophilic
human asthma, as well as RAO, which persists during disease remis-
sion.80,81 The chronic activation of peripheral blood neutrophils
reported in RAO80 could, in part, contribute to the greater disease
severity compared with IAD, whereby exposure to an inhaled stimulus
(eg, dust, mold spores) could result in an exaggerated and inappropri-
ate inflammatory response. Although such exposures can induce mild
neutrophilic pulmonary inflammation in both healthy horses and
humans, the degree of cellular activation decreases in hours/days,
even if the inciting stimulus is maintained.82,83 In contrast, if exposure
to an antigenic stimulus is maintained in horses with IAD, pulmonary
inflammation persists for up to 3 months.45 Whilst further research
into the innate immune response in IAD and RAO is required to fully
understand the role of neutrophil activation in the development of
lower airway inflammation, given that a non–Th-2 immune response
has also been associated with both IAD and RAO, the proposed exis-
tence of a “non-allergic equine asthma” phenotype currently appears
biologically appropriate.
10 | LATE-ONSET ASTHMA
Some patients (particularly women) present with asthma for the first
time as adults. These patients are less likely to be atopic, as “age of
onset” is significantly lower in patients with allergic asthma, compared
with those with non-allergic asthma.84 They also have decreased
baseline pulmonary function and are either refractory to inhaled corti-
costeroid therapy or require higher doses of inhaled corticosteroids to
achieve asthma control.33 Horses with RAO exhibit decreased base-
line pulmonary function during disease exacerbation, and tend to be
mature to older animals.1 “Inflamm-aging” describes a reduction in the
capacity of the aging body to cope with a variety of stressors together
with a progressively increasing chronic low-grade inflammatory status,
associated with aging and provoked by a continuous antigenic load.85
There are age-related increases in pro-inflammatory cytokines in both
humans and horses, with aged healthy horses having increased
expression of IL-6, IL-8, IFN-γ, and peripheral blood mononuclear cell-
derived TNF-α mRNA concentration in plasma.86 Furthermore, T-cells
of geriatric horses (>20 years) exhibit a lower proliferative response
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than those of younger animals,87 and peripheral blood lymphocytes
and monocytes derived from this cohort exhibit an increased basal
expression of IFN-γ and TNF-α mRNA, respectively.88 However, age-
related changes appear to be more tightly regulated in the lungs than
in the systemic circulation. Inflammatory cell populations in the lung
represent a balance between cellular recruitment, via airway epithelial
cell and macrophage-derived chemotactic cytokines, and removal, via
apoptosis and phagocyte-mediated clearance. Lung granulocytes (neu-
trophils and macrophages) in horses with RAO exhibit altered
apoptosis,89 which together with increased activity of transcription
factors such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-
1)90 might contribute to the maintenance of neutrophilic inflammation
in horses treated with glucocorticoids and maintained in an allergenic
environment.91 Whilst no age-related trends in BALF cytological pro-
files in horses with IAD or RAO have been reported, there is an age-
associated increase in mRNA expression of IFN-γ producing lympho-
cytes in stimulated BAL cells.88 Whilst there is a paucity of definitive
data on the progression of IAD to RAO over time, there is anecdotal
evidence suggesting the progression from IAD in younger age to RAO
in some horses. Although potentially influenced by the high preva-
lence of IAD, such a phenomenon of disease progression does warrant
further study. There is no current correlation between inflamm-aging
and the development of chronic inflammatory airway diseases. How-
ever, based on the human phenotype, we believe it is biologically
appropriate to use RAO as an equine model for late-onset asthma, as
recently reviewed.92
11 | ASTHMA WITH FIXED AIRFLOW
LIMITATION
Patients with fixed airflow obstruction are often grouped under the
heading of chronic obstructive pulmonary disease (COPD), with dis-
tinct pathological and functional characteristics compared to those
with a history of asthma93; for example, asthmatic patients do not
exhibit a loss of airways as observed in COPD.94 It is thought that
fixed airflow limitation in asthmatic patients is because of airway wall
remodeling, with both airway smooth muscle (ASM) mass and extra-
cellular matrix (ECM) deposition being increased at all levels of the
bronchial tree,95 with the increased ASM mass being the functionally
dominant alteration.96 Consequently, in addition to the clinical similar-
ities between RAO and human asthma, both diseases also share cer-
tain structural features. The structural alterations seen in human
patients with fixed airflow limitation are currently thought to be irre-
versible; however, appropriate studies are lacking to verify if indeed
this is correct. In contrast, tissue remodeling in RAO is partially revers-
ible under certain circumstances.13 In horses with RAO, long-term cor-
ticosteroid therapy (fluticasone) and antigen avoidance strategies
have been shown to significantly decrease both smooth muscle mass
(30% decrease over 3 months, but remained twice that of healthy
controls) and subepithelial collagen area.97,98 Corticosteroid adminis-
tration increased the rate of decline in smooth muscle mass, although
antigen avoidance was better at controlling airway inflammation.97
Airway remodeling in horses with IAD has not yet been investigated.
In light of the paucity of studies investigating peripheral airway
remodeling and its reversibility in human asthma and the limited data
derived from RAO horses, there is currently insufficient evidence to
determine the suitability of equine asthma as a model for asthma with
fixed airflow limitation.
12 | ASTHMA WITH OBESITY
In humans, obese patients with asthma can have moderate to severe
respiratory symptoms, with little eosinophilic airway inflammation;
there is no evidence for an increase in sputum inflammatory cells.
Whilst it is unknown whether obesity per se contributes to asthma,
there are marked alterations to respiratory physiology including an
increased demand for ventilation and work of breathing. Breathing at
low lung volumes enhances airway responsiveness which improves
after bariatric surgery.99,100 The altered mechanics of breathing that
favor airway narrowing and airway hyperresponsiveness can result in
a more severe clinical presentation than that predicted upon consider-
ation of the underlying inflammatory cytologic profile. Whilst there is
evidence that obesity increases the risk of developing asthma in peo-
ple, some studies suggest that insulin resistance, systemic IL-6 inflam-
mation and clinical features of metabolic dysfunction have a stronger
association with more severe asthma than body mass index (BMI) or
body mass.101 Whilst there is a positive correlation between both
body condition score and body fat (%) and IL-1 and TNF-α in equine
plasma,102 there is currently no report of increased expression of
inflammatory cytokines in BAL fluid or increased pulmonary resistance
in horses with obesity. Furthermore, to the best of authors' knowl-
edge there are no reports of a link between equine metabolic syn-
drome and the presence of chronic lower airway inflammation in
horses. Therefore, there is currently insufficient evidence to consider
equine asthma a suitable model for human asthma associated with
obesity.
13 | PHENOTYPE VERSUS ENDOTYPE
Our inability to identify consistent genetic and environmental correla-
tions with IAD and RAO can potentially be attributed to our limited
understanding of the various pathophysiologic mechanisms underlying
these diseases. In human medicine, “asthma endotypes” are disease
subtypes defined by their distinct, underlying pathophysiologies.103
The broad syndrome of asthma can therefore be divided into distinct
disease entities, or subtypes, on the basis of 7 variables; these include
clinical characteristics, biomarkers, lung physiology, genetics, histopa-
thology, epidemiology, and response to treatment.103 Recently, sev-
eral groups have used transcriptomic data derived from stimulated
peripheral blood mononuclear cells (ex vivo)104 and bronchial epithe-
lium (in vivo)105 to identify differentially expressed genes and path-
ways between RAO and non-RAO horses. Stimulation with hay dust
extract resulted in the greatest differential gene expression,104 the
most dominant among the upregulated genes being those involved in
immune cell trafficking, neutrophil chemotaxis, immune and inflamma-
tory responses, and cell cycle regulation and apoptosis.104,105 The
most upregulated hay dust extract-induced chemokine was
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CXCL13,104,106 a B cell chemoattractant predominantly produced by
Th17, but not Th1 or Th2, cells.107 Rather than indicating a primary
gene dysregulation, this might represent an abnormal response to
allergens in horses with RAO. Interestingly, levels of CXCL13 have
been shown to be upregulated 8-fold in BALF from human asthmatics
compared to controls.108 Furthermore, treatment of a sensitized
murine asthma model with an anti-CXCL13 antibody reduces inflam-
matory cell recruitment, bronchial-associated lymphoid tissue forma-
tion, and airway inflammation, potentially supporting CXCL13 as a
novel treatment target.108 Another potential mechanistic pathway
which could underpin the inflammatory cascade in RAO is the activa-
tion of neutrophils by the bronchial epithelium, leading to epithelial
injury and impaired repair and differentiation.105 With the develop-
ment of new biologic treatments in human asthma and the application
of more targeted therapeutic approaches in the horse, it is appropriate
to further investigate and clarify the clinical characteristics, bio-
markers, lung physiology, genetics, histopathology, epidemiology, and
response to treatment to better elucidate the pathophysiologic mech-
anisms in RAO, thus enabling the description of the allergic (Th-2),
non-allergic (non-Th-2) and late-onset endotypes of equine asthma.
14 | RESPONSE TO TREATMENT
Human asthma control is assessed in terms of both symptom control
and risk of future adverse outcomes. The level of control is the extent
to which symptoms are experienced by the patient, and is determined
by interactions between the patient's genetics, underlying disease
processes, treatment, environment, and psychosocial factors.109 In
comparison, there are multiple challenges associated with assessing
the control of signs of respiratory disease in equine asthma; therefore,
the majority of peer-reviewed studies are short-term therapeutic effi-
cacy clinical trials. As maintaining appropriate air hygiene, through a
reduction in antigen and airborne dust exposure, constitutes the most
important therapeutic and prophylactic approach to both IAD and
RAO, one of the greatest challenges in the design of clinical trials is
maintaining a degree of control over environmental exposures. Cur-
rently, there is a need for a long-term longitudinal study assessing the
relative and combined beneficial effects of both drug therapy and
environmental management on the control of IAD clinical signs.
Indeed, even clinical research on the efficacy of treatments on airway
hypersensitivity and hyperreactivity in IAD cases is limited,110 with
treatment decisions typically based on clinical experience, data
derived from horses with RAO, or both.1,111 Initially, therapeutic trials
in RAO focused primarily on the beneficial effects of bronchodilators,
in light of the lower airway obstruction and increased respiratory
effort at rest exhibited by these cases. Recently, however, the thera-
peutic research focus in equine asthma has partly shifted towards the
control of airway inflammation.
Airway inflammation is due in part to the increased activity of
transcription factors that in turn lead to an increased production of
inflammatory mediators and recruitment of inflammatory cells. There-
fore, the efficacy of anti-inflammatory drugs, such as corticosteroids,
in RAO has partly been evaluated via their influence on the expression
of selected inflammatory genes in both BALF-derived cells98,112,113
and bronchial epithelium.113 Additionally, airway cytology has been
used as a marker of therapeutic success with a reduction in airway
neutrophilia being achieved by transferring horses to a low dust feed,
with a greater level of improvement achieved by the additional admin-
istration of oral dexamethasone.113 However, in most studies, cortico-
steroids as sole therapy, whether administered systemically or by
inhalation, failed to normalize the airway neutrophilia, even after up
to 6 months of treatment, and this might also be true in
IAD.97,98,110,114,115 However, glucocorticoid therapy downregulates
some of the neutrophil functions in the airways of horses with
RAO.116 Compared to the use of low dust feed alone, dexamethasone
administration resulted in a decreased expression of IL-8, chemokine
(C-X-C motif ) ligand 2 (CXCL2), and IL-1β in BALF-derived cells;
whereas, both treatments decreased expression of IL-8 and CXCL2 in
airway epithelium, compared to baseline.113 Similarly, low dust feed
resulted in a greater decrease of IL-8 expression than that of inhaled
fluticasone.97 Furthermore, as the anti-inflammatory properties of glu-
cocorticoids are thought to be mediated by suppression of inflamma-
tory gene expression via inhibition of transcription factors NF-κB and
AP-1, the effect of glucocorticoid administration on these factors in
BALF-derived cells and bronchial epithelium in horses with RAO have
also been investigated: no significant treatment effect was observed
on the expression of either transcription factor.91 There are currently
no published studies assessing the effects of glucocorticoid adminis-
tration on the activity of transcription factors beyond a treatment
period of 2 weeks.
New immunomodulatory agents have been investigated in both
human and equine allergic (Th-2) asthma. Recently, nonspecific CpG-
GNP (nanoparticle-bound cytosine-phosphate-guanosine oligodeoxy-
nucleotides) based immunotherapy was shown to provide an effec-
tive, allergen-independent approach to treatment of horses with
RAO.117 Briefly, CpG is recognized by Toll-like receptors (TLR9), that
are expressed in equine pulmonary neutrophils, macrophages, and epi-
thelial cells.118 Ligand-binding results in the stimulation of Th-1
response, leading to the downregulation of any Th-2 bias associated
with an allergenic trigger (as in seen during an RAO exacerbation).
Furthermore, Treg lymphocytes are stimulated, helping to re-establish
T-helper cell homeostasis.
15 | CONCLUSIONS
Upon consideration of the shared factors between human asthma,
IAD and RAO, we conclude that adoption of the term equine asthma
is appropriate, whilst acknowledging that important heterogeneity
exists within this broad disease category. We therefore support the
proposal that the term mild/moderate equine asthma replace IAD and
severe equine asthma replace RAO in the literature from this point
onwards, whilst recognizing the need to preserve the spectrum of dis-
eases which fall within the proposed new “equine asthma” classifica-
tion. Furthermore, in addition to the subcategorization of equine
asthma based on severity, we propose that equine equivalents to spe-
cific human asthma phenotypes exist, based on shared clinical and
pathophysiological characteristics. Finally, with the development of
new biologic treatments in human asthma and the application of more
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targeted therapeutic approaches in the horse, it might be appropriate
to further investigate and clarify the allergic (Th-2), non-allergic (non–
Th-2) and late-onset phenotypes of equine asthma; however, further
research is required to more fully determine the potential clinical util-
ity of such a phenotypic classification exercise. Currently, there is
insufficient evidence to recommend an equine model for asthma with
fixed airflow limitation, and asthma in obese patients.
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